Actively Recruiting
Comparison of Bone Microarchitecture Analysed by HRpQCT and pQCT in Pathologies With Bone Loss and/or Muscle Loss
Led by Centre Hospitalier Universitaire de Saint Etienne · Updated on 2026-03-03
1000
Participants Needed
1
Research Sites
482 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study aims to utilize medical devices, such as the Xtreme CT and XCT 3000, to assess bone and muscle microarchitecture for various pathologies. The devices provide crucial data on bone and muscle density, aiding in understanding fracture risks associated with conditions like rheumatoid arthritis and neurological disorders. Current methods like DXA scanning have limitations in predicting fracture risks accurately due to their inability to assess cortical and trabecular microstructure. The study emphasizes the importance of evaluating cortical porosity and trabecular volume loss, especially in conditions like post-menopausal osteoporosis and sarcopenia. Additionally, it explores the impact of neurological disorders, renal insufficiency, and endocrinopathies on bone health. Furthermore, the study aims to establish a control group to differentiate pathological changes from age-related variations. Expected outcomes include a comprehensive understanding of bone microarchitecture alterations across various pathologies and the potential to improve fracture risk estimation beyond conventional methods like DEXA scanning. Ultimately, the study anticipates facilitating better management strategies to reduce fracture risks associated with these conditions.
CONDITIONS
Official Title
Comparison of Bone Microarchitecture Analysed by HRpQCT and pQCT in Pathologies With Bone Loss and/or Muscle Loss
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women or men treated at Saint-Etienne University Hospital with osteoporosis risk and one of the following: history of brittle bone fracture, bone fragility needing densitometry, inflammatory joint disease (rheumatoid arthritis or spondyloarthritis), chronic kidney disease, endocrinopathies (primary hyperparathyroidism, constitutional thinness, anorexia nervosa, obesity with BMI >30, sarcopenia), or neuropathies like Parkinson's disease
- Controls with acute spinal or radicular pain episode less than one month old treated with corticosteroids for less than one month
- Signed written consent
You will not qualify if you...
- Lack of signed written consent
- Controls using medications causing bone loss for at least 6 months such as anti-aromasin, GnRH agonist, corticosteroids (≥5 mg/day), or anti-epileptic drugs (carbamazepine, phenobarbital, phenytoin, primidone, valproic acid)
- History of fracture due to bone fragility
- Taking bone-targeting medications like biphosphonate, teriparatide, or strontium ranelate
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chu Saint Etienne
Saint-Etienne, France, 42055
Actively Recruiting
Research Team
H
Hubert MAROTTE, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here